checkAd
    Startseite > Aktien > Axsome Therapeutics > Nachrichten
    Axsome Therapeutics Aktie
    67,72
     
    EUR
    -1,05 %
    -0,72 EUR
    Letzter Kurs 31.05.24 Tradegate
    66,34
     
    EUR
    75 STK
    Geldkurs 31.05.24
    69,06
     
    EUR
    72 STK
    Briefkurs 31.05.24
    ISIN: US05464T1043 · WKN: A2AA7B · SYM: 19X · USA

    Neueste Nachrichten

    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    30.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
    29.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
    28.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics to Present at Upcoming Investor Conferences
    08.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    06.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Recognizes May as Mental Health Awareness Month
    01.05.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
    15.04.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
    10.04.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
    01.04.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
    25.03.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
    25.03.24 · globenewswire · Axsome Therapeutics
    Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
    19.03.24 · globenewswire · Axsome Therapeutics